Professional Documents
Culture Documents
product shelf-life
(1)
Storage Time
Storage Condition (Temperature, Humidity, Light, Oxygen)
Dosage Form (Tablet, Capsule, Vial)
Manufacturing Procedure
Packaging
Formulation (Composition, Quantity, Quality of excipients and API)
(2)
Temperature
- the kinetic of a degradation can be described by the Arrhenius equation
- for evaluation you need the accelerated condition
k=A*exp(-Ea/R*T)
k: is the rate coefficient; A: is a constant; Ea: is the activation energy
R: is the universal gas constant; T: is the temperature (in Kelvin)
A historically useful generalization supported by the Arrhenius equation is that,
for many common chemical reactions at room temperature, the reaction rate
doubles for every 10 degree Celsius increase in temperature
(3)
Humidity
- may influence degradation; hydrolysis
- for evaluation you need different humidity, packaging configuration
Light
- may influence degradation; photoreaction
- for evaluation you need photo stability testing
Oxygen
- may influence degradation; oxidation
- for evaluation you need different packaging configuration
Packaging configuration
- no temperature protection
- light protection
- humidity protection
humidity protection (water vapour permeability) of blisters
PVC- < Duplex- / Triplex- < Alu- blisters
humidity protection (water vapour permeability) of bottles
HDPE- bottles < Glass- bottles
(4)
(5)
Formulation
Fixed dose combination finished pharmaceutical product (FDC-FPP)
Def.: A finished pharmaceutical product that contains two or more actives
- May have an impact on the stability, the APIs may react with each other
- The most sensible API will trigger the shelf-life
- Testing has to take all APIs into account (assay, degradation, dissolution)
(1)
(2)
(3)
Significant change
5% change in assay from its initial value
Any degradation product exceeding its acceptance criteria
Failure to meet the acceptance criteria for appearance, physical attributes and
functionality test (e.g. color, phase separation, caking, hardness)
Also, as appropriate for the dosage form;
- failure to meet the acceptance criteria for pH
- failure to meet acceptance criteria for dissolution for 12 dosage units
(4)
Statistical Approach
- Regression analysis (linear, non-linear)
(5)
Available
long-term
data [X]
Change or
variability over
time
Available
accelerated
data
Change or
variability over
time
little or no
6 month
little or no
Showing change
and / or
variability over
time
6 month
Showing change
and / or
variability over
time
(12 month)
(18 month)
X
(12 month)
(18 month)
statistical
analysis
(1)
(2)
Galenical Formulation
Ampoules
Vials
Strength
Appearance
Color
Odor
Clarity
Moisture
Dissolution
pH
Viscosity
Resuspendability/redispersiblity
Separation
Weightloss
Homogeneity
Particulate/matter/size
Extractables
Pyrogenicity
Sterility/microbial limit
Preservatives
Container closure integrity
Other recommendations
Emulsions
+
+
+
+
+
+
+
+
c). d)
Oral
Solution
and
suspensions
+
+
+
+
+
+
+
+
+
d)
Aerosols
+
+
+
e)
(3)
Topical
SmallLargeand
volume
volume
ophthalmic parenterals parenterals
+
+
+
+
+
+
+
+
+
+
+
+
+
+
f)
+
+
+
+a
+
+a
+ a)
+
+ b)
+
+
+
+
d)
+
+
+
+b)
+
+b)
+
+
+
d)
b)
c)
Heating/cooling cycle 4C
45C
d)
e)
Conclusion
Quality is designed and built into a product and not tested in!
Stability has to be planned during lifecycle of the product with standardized
conditions
We Innovate Healthcare